Cadastre-se e crie alertas para ativos, eventos econômicos como também artigos de colaboradores
Cadastre-se grátis Já possui uma conta? Login
14,35
+0,04
+0,28%
Cotações
Todos os tipos de ativos
- Todos os tipos de ativos
- Índices
- Ações
- ETFs
- Fundos
- Commodities
- Moedas
- Cripto
- Título
- Certificados
Por favor, tente outra busca
Libere dados premium: até 50% de desconto InvestingPro GARANTA JÁ SUA OFERTA
Eaton Vance Worldwide Health Sciences Fund Class A (ETHSX)
Adicionar/Remover de uma Carteira
Adicionar à carteira
- Classificação da Morningstar:
- Total de ativos: 715,71M
Eaton Vance Worldwide Health Sci A
14,35
+0,04
+0,28%
ETHSX - Visão Geral
Nesta página, você encontrará um perfil aprofundado de Eaton Vance Worldwide Health Sciences Fund Class A. Saiba mais sobre informações de gestão, ativos totais, estratégia de investimento e dados de contato de ETHSX, entre outras informações.
Informações de Contato
Endereço
Two International Place
Boston,MA 02110
United States
Boston,MA 02110
United States
Telefone
+1 8008362414
Site
www.eatonvance.com
Principais Executivos
| Nome | Título | Desde | Até |
|---|---|---|---|
| Jason A. Kritzer | Vice President | 2016 | Agora |
| Biografia | Mr. Kritzer is a Vice President of Eaton Vance. Prior to joining Eaton Vance in 2012, Mr. Kritzer was a director and equity analyst at BlackRock , Inc. covering the healthcare sector since 2006. | ||
| Samantha Pandolfi | Vice President | 2016 | Agora |
| Biografia | Ms. Pandolfi is a Vice President of EVAIL. Prior to joining EVAIL, Ms. Pandolfi held similar positions at EVMI. Prior to joining EVMI as a Vice President in November 2015, Ms. Pandolfi was a Portfolio Manager and Research Analyst with Goldman Sachs Asset Management over her fifteen year tenure (2000-2015). | ||
| Sven H. Borho | Founding General Partner | 2005 | 2016 |
| Biografia | Sven H. Borho, CFA, is a founding General Partner of OrbiMed. Mr. Borho is a portfolio manager for OrbiMed’s public equity funds and he heads the firm’s trading efforts. He started his career in 1991 when he joined Mehta and Isaly as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Mr. Borho became portfolio manager to investment funds under management. Mr. Borho studied business administration at Bayreuth University in Germany and received a M. Sc. (Econ.) from The London School of Economics; he is a citizen of both Germany and Sweden. | ||
| Richard D. Klemm | Biotechnology Analyst | 2005 | 2016 |
| Biografia | Klemm joined OrbiMed in 2000 as a biotechnology analyst. Klemm has earned the right to use the Chartered Financial Analyst designation. | ||
| Geoffrey C. Hsu | Biotechnology Analyst | 2005 | 2016 |
| Biografia | Hsu joined OrbiMed in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Hsu has earned the right to use the Chartered Financial Analyst designation. | ||
| Trevor M. Polischuk | Analyst | 2005 | 2016 |
| Biografia | Polischuk joined OrbiMed in 2003 as an analyst covering the major global pharmaceutical industry. Previously, he worked at Lehman Brothers as a senior research analyst covering the U.S. pharmaceutical industry. | ||
| Samuel David Isaly | Portfolio Manager | 1985 | 2016 |
| Biografia | Samuel D. Isaly founded Exome in 2018 and is the Managing Member. Mr. Isaly is one of the world’s most recognized healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Mr. Isaly has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, and S.G. Warburg. Isaly was a portfolio manager with OrbiMed Advisors. Previously, he was a president and partner with Mehta and Isaly Asset Management. From 1986 to 1989, he was a senior vice president with S.G. Warburg & Company. He also spent more than three years as a partner with Gramercy Associates, one and a half years as a vice president with Merrill Lynch & Company, and two years as a vice president with Chase Manhattan Bank. | ||
| Bernard Graham | - | 1985 | 1989 |
Escreva o que você pensa sobre Eaton Vance Worldwide Health Sciences Fund Class A
Tem certeza que deseja excluir esse gráfico?
Apagar Cancelar
Substituir o gráfico anexado por um novo gráfico?
Substituir Cancelar
Diretrizes para Comentários
Anexar um gráfico a um comentário
Confirmar bloqueio
Tem certeza de que deseja bloquear %USER_NAME%?
Ao confirmar o bloqueio, você e %USER_NAME% não poderão ver o que cada um de vocês posta no Investing.com.
%USER_NAME% foi adicionado com êxito à sua Lista de bloqueios
Já que acabou de desbloquear esta pessoa, você deve aguardar 48 horas antes de bloqueá-la novamente.
Denunciar esse comentário
Diga-nos o que achou desse comentário
Comentário denunciado
Obrigado!
Seu comentário foi enviado aos moderadores para revisão